Current perspectives on the role of bioresorbable scaffolds in the management of coronary artery disease by unknown
Address for correspondence:  
Dariusz Dudek, MD, PhD, FESC, Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, ul. Kopernika 17,  
31–501 Kraków, Poland, tel: +48 12 424 71 81, fax: +48 12 424 71 84, e-mail: mcdudek@cyfronet.pl
Received: 12.06.2018 Accepted: 12.06.2018 Available as AoP: 12.06.2018
Kardiologia Polska Copyright © Polish Cardiac Society 2018
Current perspectives on the role  
of bioresorbable scaffolds in the management  
of coronary artery disease
Artur Dziewierz1, Dariusz Dudek2 
12nd Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland 
2Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
A b s t r a c t
New-generation drug-eluting stents are recommended as the default option in all clinical conditions and lesion subsets in 
patients undergoing percutaneous coronary intervention (PCI). On the other hand, despite achieving very good results in the 
rate of restenosis, permanent delivery of a metallic platform is affected by several drawbacks, such as caging of the vessel, side 
branch jailing, impairment of vasomotion, and the impossibility of lumen enlargement. Also, the presence of residual foreign 
material may increase the risk of late and very late stent thrombosis and support the need for long-term dual antiplatelet 
therapy after PCI. These pending limitations of metallic stents can be addressed by the implantation of bioresorbable scaf-
folds (BRSs). At present, there are numerous devices available for preclinical or clinical evaluation. This review discusses the 
evidence for BRS in the management of patients with coronary artery disease.
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INTRODUCTION
Over 40 years have passed since Andreas Gruentzig performed 
the first successful percutaneous coronary angioplasty of the 
proximal left anterior descending artery. Since then, rapid 
development in percutaneous interventional techniques has 
been observed, including the introduction of the bare-metal 
stent (BMS) and the drug-eluting stent (DES). Importantly, it 
has been shown that stent implantation during percutaneous 
coronary intervention (PCI) reduces the risk of acute compli-
cations of PCI, as compared to balloon angioplasty alone [1]. 
Also, it reduces the risk of target-lesion (TLR) and target-vessel 
revascularisation (TVR), especially with the use of DES [2, 3]. 
New-generation DESs have become the epitome of clinical 
performance, and their use is recommended in almost every 
clinical and angiographic scenario in patients with coronary 
artery disease (CAD) [4–7]. However, despite achieving very 
good results in the rate of TLR/TVR with DES, permanent de-
livery of a metallic platform is affected by several drawbacks, 
such as caging of the vessel, side branch jailing, impairment 
of vasomotion, and the impossibility of lumen enlargement 
[8–10]. Also, the presence of residual foreign material may 
increase the risk of late and very late stent thrombosis and sup-
port the need for long-term dual antiplatelet therapy (DAPT) 
after PCI [8–10]. Trapping the coronary artery in a metallic 
cage, especially the mid-portion of the left anterior descend-
ing coronary artery, may exclude the possibility of future graft 
anastomosis in case of the need for coronary artery bypass 
grafting. These pending limitations of metallic stents can be 
addressed by the implantation of bioresorbable scaffolds 
(BRSs) [8–10]. Over the last two decades, considerable effort 
has been made to develop new fully bioresorbable devices. At 
present, there are numerous devices available for preclinical 
or clinical evaluation [8, 10–13]. This review discusses the 
evidence for BRS in the management of patients with CAD.
BIORESORBABLE SCAFFOLDS:  
CONCEPT AND AVAILABLE DEVICES
Bioresorbable scaffolds, also known as fully bioresorbable 
stents, were designed to provide temporary mechanical scaf-
folding within months to years after implantation and subse-
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quently undergo bioresorption. Regarding the composition of 
the backbone, BRS may be identified as polymeric (composed 
of polylactic acid or related compounds) or metallic (com-
posed of magnesium alloy) [12]. Apart from the backbone, 
they typically consist of a biodegradable polymer matrix and 
an antiproliferative drug. The acute performance of a scaffold 
should mimic that of DES (good deliverability, minimum acute 
recoil). The resorption process of BRS progresses gradually, 
mainly due to hydrolysis; thus, minimal or no inflammation 
can be observed. Complete bioresorption of BRS results in 
vessel uncaging and was believed to be associated with sub-
sequent restoration of vasomotion and endothelial function 
(vascular restoration therapy) [9]. Another important part of 
this concept is restoration of low thrombogenic milieu which 
may lead to reduced risk of very late in-scaffold thrombosis 
and no need of prolonged DAPT. In addition, a better control 
of vascular healing followed by a reduced risk of neoathero-
sclerosis after BRS was expected. 
So far, five BRSs have received the approval of the Com-
munauté Européenne (CE): the Absorb bioresorbable vascular 
scaffold 1.1 (Abbott Vascular, CA, USA), the DESolve scaffold 
(Elixir Medical, CA, USA), the Fantom scaffold (Reva Medi-
cal, CA, USA), the ART (Arterial Remodelling Technologies, 
France), and the Magmaris (Biotronik, Germany). All of them 
save the last one are polymeric BRSs. The key features of these 
BRSs are summarised in Table 1.
ABSORB BIORESORBABLE SCAFFOLD
The Absorb bioresorbable vascular scaffold consists of 
a polymer backbone of poly-L-lactide (PLLA) coated with 
poly-D,L-lactide (PDLLA), which contains and controls the 
release of everolimus (Fig. 1A). The Absorb received CE 
mark approval in January 2011. However, due to some safety 
concerns, discussed above, since September 2017 it has no 
longer been available on the European market [14].
Initial studies showed late lumen enlargement as well 
as restoration of vasomotion and endothelial function at two 
years after the Absorb implantation [15]. In this initial, highly 
selected cohort of patients excellent clinical performance with 
no events of very late device thrombosis was confirmed. A case 
example of an Absorb implantation is depicted in Figure 2. 
Also, several registries have confirmed the feasibility of the 
Absorb implantation for so-called “off-label” indications [16, 
17], i.e. acute coronary syndromes [18–20], bifurcations [21], 
saphenous vein grafts [22], chronic total occlusions, etc. How-
ever, results of the European multicentre GHOST-EU registry 
suggest an elevated risk of definite or probable device throm-
bosis in patients treated with the Absorb in the “real-world” 
setting (1.5% at 30 days and 2.1% at six months) [23]. 
Several randomised studies and their meta-analyses 
assessed the clinical performance of the device (Figs. 3, 4). 
The largest of them was the ABSORB III study, which en-
rolled 2008 patients with stable or unstable angina, who 
were randomly assigned in a 2:1 ratio to receive the Absorb Ta
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(1322 patients) or an everolimus-eluting cobalt-chromium 
(Xience) stent (686 patients) [24]. The primary endpoint 
was the target-lesion failure (TLF) defined as a composite 
of cardiac death, target-vessel myocardial infarction (MI), or 
ischaemia-driven TLR at one year, and it was tested for both 
non-inferiority and superiority. At one year, the rate of TLF 
was higher in patients treated with the Absorb than with the 
Xience (7.8% vs. 6.1%; p = 0.007 for non-inferiority and 
Figure 1. Examples of available bioresorbable scaffold technologies: A. Absorb (Abbott Vascular, CA, USA); B. Fantom (Reva 
Medical, CA, USA); C. Magmaris (Biotronik, Germany); D. Fantom (Reva Medical, CA, USA); E. Unity (QualiMed, Germany);  
F. MeRes100 (Meril Life Sciences, India); G. Mirage (Manli Cardiology, Singapore). Reproduced with permission from each company
Figure 2. A case example of a 60-year-old male patient with stable angina treated with Absorb scaffold (the ABSORB study);  
A. Baseline angiography with 80% stenosis of the left anterior descending artery; B. Final angiography after successful implantation 
of the Absorb scaffold 3.0 × 12 mm up to 14 atm and postdilatation with non-compliant balloon 3.0 × 6 mm up to 16 atm;  
C. Eleven-year control angiography before planned aortic valve surgery with a maintained optimal result of scaffold implantation; 
D. Eleven-year control optical coherence tomography with a complete dissolution of the scaffold and so-called “golden-tube” 
picture (remodelling with lumen enlargement, vessel wall thinning, and pseudo-atheroregression caused by vascular reparative 
therapy with a bioresorbable scaffold)
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Figure 3. Two-year target lesion failure (A) and definite/probable device thrombosis (B) in major randomised clinical trials with 
the Absorb [29]; BRS — bioresorbable scaffold; CoCr-EES — cobalt-chromium-everolimus-eluting stent
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Figure 4. Three-year target lesion failure (A) and definite/probable device thrombosis (B) in major randomised clinical trials with 
the Absorb [30]; BRS — bioresorbable scaffold; CoCr-EES — cobalt-chromium-everolimus-eluting stent
A
B
p = 0.16 for superiority). Also, the rate of device thrombosis 
was numerically higher (two times) for the Absorb (1.5% 
vs. 0.7%; p = 0.13). Importantly, no differences in the rate 
of cardiac death, target-vessel MI, and ischaemia-driven TLR 
were observed. Interestingly, the difference in the rate of TLF 
was no longer significant at three years (13.4% vs. 10.4%; 
p = 0.06). However, the rates of target-vessel MI (8.6% 
vs. 5.9%; p = 0.03) and device thrombosis (2.3% vs. 0.7%; 
p = 0.01) were higher for the Absorb [25]. Importantly, for 
patients treated with the Absorb, the treatment of very small 
vessels (reference vessel diameter [RVD] < 2.25 mm) was 
identified as an independent predictor of three-year TLF and 
scaffold thrombosis.
The second large randomised study was the AIDA, 
which enrolled 1845 patients undergoing PCI, who received 
either the Absorb (924 patients) or a metallic stent (Xience, 
921 patients) [26]. In the study, more than half of the patients 
had an acute coronary syndrome. Similarly to the ABSORB III 
study, the primary endpoint was target-vessel failure (TVF; 
a composite of cardiac death, target-vessel MI, or TVR). Due 
to safety concerns, the data and safety monitoring board 
recommended early reporting of the study results. At two 
years the rates of TVF (11.7% vs. 10.7%; p = 0.43) and 
cardiac death (2.0% vs. 2.7%) were comparable in patients 
treated with the Absorb and the Xience stent. However, the 
risk of definite or probable device thrombosis after two years 
was almost four times higher for the Absorb (3.5% vs. 0.9%; 
p < 0.001) [26].
Another study is ABSORB IV, from which initial, 30-day 
results were recently presented [Stone, TCT 2017]. In this 
study, 2604 patients were randomly assigned to either the 
Absorb (n = 1296) or the Xience (n = 1308) stent. In contrast 
to previous ABSORB studies, an expanded patient popula-
tion including patients with acute coronary syndromes was 
enrolled. In addition, avoidance of small vessels was man-
dated, and optimal implantation technique with aggressive 
predilatation and routine high-pressure postdilatation were 
encouraged. At 30 days, the Absorb was not inferior to the 
Xience regarding TLF (the primary endpoint, 5.0% vs. 3.7%; 
p = 0.02 for non-inferiority, p = 0.11 for superiority). A trend 
towards an increased risk of device thrombosis was reported 
for the Absorb (0.6% vs. 0.2%; p = 0.06). Interestingly, after 
the exclusion of patients with acute coronary syndromes 
(ABSORB III study-like population) the risk of device throm-
bosis dropped to 0.4% vs. 0.0% (Fig. 5). These results suggest 
that, compared to ABSORB III, reducing the number of very 
small vessels treated in ABSORB IV substantially reduced 
the device thrombosis for BRS, but also for the Xience stent.
Several meta-analyses were conducted to compare 
outcomes of the Absorb vs. the Xience stent. For instance, 
in a meta-analysis of 3738 patients from six trials (ABSORB 
China, ABSORB II, ABSORB III, ABSORB Japan, EVERBIO II, 
TROFI II) the rates of TVF, TLR, MI, and death at one year 
were comparable for patients treated with the Absorb and 
the Xience stent [27]. However, the risk of definite or prob-
able device thrombosis was higher for the Absorb (odds ratio 
[OR] 1.99; 95% confidence interval [CI] 1.00–3.98; p = 0.05) 
and even more pronounced between 1 and 30 days after 
implantation (OR 3.11; 95% CI 1.24–7.82; p = 0.02) [27]. 
A patient-level, pooled meta-analysis of 3389 patients 
from four randomised studies (ABSORB China, ABSORB II, 
ABSORB III, ABSORB Japan) did not confirm these find-
ings; the rates of TVF and device thrombosis at one year 
were comparable between groups [28]. On the other hand, 
the meta-analysis by Ali et al. [29] of two-year outcomes of 
5583 patients from seven randomised trials showed a higher 
risk of TVF in patients treated with the Absorb (9.4% vs. 7.4%; 
p = 0.0059; Fig. 3). This difference was driven by increased 
rates of target-vessel MI and ischaemia-driven TLR. Also, 
the two-year cumulative incidence of device thrombosis 
Figure 5. Thirty-day definite/probable device thrombosis in ABSORB III and IV studies. A total of 1918 (73.7%) patients enrolled 
in ABSORB IV fulfilled ABSORB III study criteria — “ABSORB III-like”, and 686 did not (20.8% acute myocardial infarction, 0.5% 
three lesions treated, 2.1% thrombus) [Stone, TCT 2017]; BRS — bioresorbable scaffold; CI — confidence interval; CoCr-EES 
— cobalt-chromium-everolimus-eluting stent; HR — hazard ratio
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was higher for the Absorb than for the Xience stent (2.3% 
vs. 0.7%; p < 0.001). Interestingly, a landmark analysis be-
tween one and two years confirmed higher rates of TVF (3.3% 
vs. 1.9%; p = 0.0376) and device thrombosis (0.5% vs. 0.0%; 
p < 0.001) in patients treated with the Absorb [29]. These 
findings were strengthened by a recent individual-patient-data 
pooled meta-analysis of 3389 patients from four ABSORB trials 
[30]. In this meta-analysis, implantation of the Absorb was as-
sociated with higher three-year rates of TVF (11.7% vs. 8.1%; 
p = 0.006), target-vessel MI (7.8% vs. 4.2%; p = 0.0006), and 
ischaemia-driven TLR (6.6% vs. 4.4%; p = 0.02), with com-
parable cardiac mortality (1.1% vs. 1.1%; p = 0.85; Fig. 4). 
The risk of device thrombosis at three years was higher for 
BRS (2.4% vs. 0.6%; p = 0.001). In addition, between one 
and three years, TVF (6.1% vs. 3.9%; p = 0.02) and device 
thrombosis (1.1% vs. 0.0%; p < 0.001) were higher for the 
Absorb [30]. A recent network meta-analysis by Kang et al. 
[31] provides some data on the indirect comparison of the 
long-term clinical performance of the Absorb in compari-
son to other metallic BMSs and DESs. This meta-analysis of 
105,842 patients from 91 randomised controlled trials with 
a mean follow-up of 3.7 years concluded that patients treated 
with the Absorb had a significantly higher risk of definite or 
probable device thrombosis as compared to those treated with 
metallic DESs. Also, the risk of very late device thrombosis was 
highest with the Absorb among comparators. Interestingly, the 
risk of device thrombosis for BRS was higher than assumed 
from BMS and first-generation DES. However, this indirect 
evidence seems to be rather weak [31].
The results of the above-discussed studies suggest an 
increased and persistent risk of device thrombosis even at two 
to three years after scaffold implantation. This finding is some-
what contrary to the concept of vascular restoration with BRS, 
which was believed to be associated with improved long-term 
safety [9]. There are several possible factors suggested to be 
linked to this phenomenon. First, higher thrombogenicity 
might be observed with BRS, particularly in cases where a sub-
optimal deployment technique was used in combination with 
relatively large strut thickness of the scaffold. As confirmed by 
optical coherence tomography as well as an ex vivo animal 
model, the large strut thickness of the Absorb may induce local 
haemodynamic alterations leading to platelet activation and 
increased acute thrombogenicity. Second, thrombogenicity 
and local inflammation might be induced by the breakdown 
products and/or the extracellular matrix replacing the strut 
void [12, 32–34]. Third, similarly to metallic DES, incomplete 
lesion coverage, underexpansion, and strut malapposition 
were shown to be linked to the Absorb thrombosis [35–37]. 
However, these might be expected more frequently with the 
Absorb due to its physical properties and a higher possibility 
of acute recoil and strut fracture as compared to metallic DES. 
Also, specifically for BRS technologies, the loss of integrity of 
the scaffold backbone as a result of bioresorption may lead 
to prolapse of part of the scaffold into the vessel lumen and 
possible disturbances of coronary blood flow [12, 32–34, 37]. 
In addition, a recent substudy of the ABSORB EXTEND trial 
has suggested the occurrence and progression of in-scaffold 
neoatherosclerosis with luminal narrowing five years after 
Absorb scaffold implantation [38].
Importantly, the risk of thrombotic events after Absorb 
implantation may be diminished by proper patient and lesion 
selection, as well as the optimisation of scaffold implanta-
tion. For instance, the benefit of standardised implantation 
technique in the reduction of scaffold thrombosis was con-
firmed [39]. This standardised protocol included pre-dilation 
with noncompliant balloon up to the same size as the RVD, 
confirmation of proper vessel dilatation, implantation of the 
Absorb of the same size as the RVD at 10 to 12 atm, and finally 
postdilatation with noncompliant balloons up to a maximum 
of 0.5 mm larger at 14 to 16 atm. In addition, other stud-
ies have confirmed the impact of vessel sizing and operator 
technique on achieved outcomes after Absorb implantation 
[40–42]. Prolonged DAPT may limit the risk of scaffold throm-
bosis. However, the choice and duration of DAPT after BRS 
have not been clearly defined or tested in randomised studies 
[12]. A recent expert review suggests that DAPT should be 
continued for at least 12 months after BRS, with an option of 
prolongation up to 24 months and beyond in selected patients 
and lesions (i.e. complex lesions; > one BRS implanted; other 
unfavourable clinical, angiographic, and procedural character-
istics) [43]. It should be considered if no significant bleeding 
issues arise during the first 12 months. Similarly, a report of 
the European Society of Cardiology-European Association of 
Percutaneous Cardiovascular Interventions (ESC-EAPCI) Task 
Force on the evaluation and use of BRS recommends prolon-
gation of the DAPT for the expected duration of bioresorption 
for a given BRS (e.g. ≥ 36 months after the Absorb) [12]. It is 
unknown whether the use of ticagrelor or prasugrel has a more 
protective effect against scaffold thrombosis than clopidogrel. 
However, it is obvious that patients who cannot tolerate or 
are unlikely to be compliant with extended-duration DAPT, 
including patients on oral anticoagulants, are not good can-
didates for BRS [12].
Another suggested benefit of BRS is the recovery of the 
vasomotor response, which is said to be associated with 
a lower incidence of angina and ischaemia under stress 
conditions. A detailed analysis of the ABSORB Cohort B 
study confirmed only a numerical increase of the vasomotor 
response to nitroglycerine after the Absorb scaffold implan-
tation measured by mean lumen diameter. Importantly, the 
vasomotor response trended to moderately increase, which 
is consistent with the progressive degradation and bioresorp-
tion of the scaffold, but the degree of vasomotor response 
remained lower in comparison with adjacent segments [44]. 
Surprisingly, the same degree of vasomotion restoration and 
angina relief was confirmed for the Xience DES [45, 46].
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DESOLVE BIORESORBABLE SCAFFOLD
The DESolve scaffold is a novolimus-eluting polymeric BRS, 
which received CE mark approval in May 2014 (Fig. 1D). The 
first generation of DESolve had 150-µm strut thickness, and 
the currently available second generation, DESolve Cx PLUS, 
has 120-µm struts [47]. The DESolve scaffold differs from the 
Absorb and other polymeric BRS scaffolds by its early degra-
dation and resorption profile (> 90% polymer degradation at 
six months and ~70% polymer bioresorption at 12 months). 
The DESolve scaffold also provides a larger range of expan-
sion and uniquely exhibits a self-correction feature, which 
can resolve minor malapposition to the vessel wall [47, 48]. 
In a study involving 72 patients, wherein the acute mechani-
cal performance of the DESolve scaffold was compared with 
the Absorb scaffold in terms of appropriate deployment with 
optical coherence tomography, the DESolve scaffold showed 
a trend towards a lower residual in-scaffold area stenosis and 
a larger maximum and minimum scaffold diameter [49]. So far, 
randomised clinical data on the head-to-head comparison of 
the DESolve with other BRSs or metallic DESs are not available. 
However, the propensity-score matching analysis suggested 
no differences in clinical performance of the Absorb vs. the 
DESolve BRS at one year (TVF 4.7% vs. 4.5%; p = 0.851, 
definite device thrombosis 2.0% vs. 1.0%; p = 0.529) [50]. 
The DESolve Nx clinical study involving 126 patients showed 
a high device and procedural success and low rates of adverse 
events, including low device thrombosis (0.8%), through 
24 months [51]. Serial intravascular ultrasound evaluation 
showed an increase in the device and lumen dimensions be-
tween baseline and six months, with no detectable footprints 
of the scaffold at 18 months [52]. Furthermore, in the DESolve 
PMCF study involving 102 patients with CAD, a low rate of 
TVF (3.0%) and device thrombosis (1.0%) was observed at 
12 months [53]. Real-world data of the DESolve scaffold show 
high rates of successful scaffold implantations with low rates 
of periprocedural complications and major adverse cardiac 
events in long-term follow-up [54]. The initial experience 
with a new generation DESolve Cx has shown no ischaemic 
events and device thrombosis at 12 months after implantation 
[Abizaid et al., TCT 2017].
FANTOM BIORESORBABLE SCAFFOLD
The Fantom scaffold is a sirolimus-eluting BRS made princi-
pally from an iodinated polycarbonate copolymer of tyrosine 
analogues (desaminotyrosine) and biocompatible hydroxyes-
ters (Fig. 1B) [55]. The CE mark approval for the device was 
granted in April 2017. Despite a strut thickness of 125 µm, 
the design and structural properties of the polymer afford 
radial strength comparable to or greater than contemporary 
metallic DESs, with low rates of recoil. In addition, unlike 
other available polymer BRSs, the Fantom consists of unique 
radiopaque polymer, which may facilitate device positioning. 
Moreover, this design allows rapid inflation during deployment 
similar to a metal stent. However, limited data are available 
on clinical outcomes after Fantom scaffold implantation. 
In the FANTOM II study (Cohort A) [55], a total of 117 pa-
tients with a single de novo lesion ≤ 20 mm and RVD 2.5 to 
3.5 mm were enrolled. Binary restenosis was noted in 2.0% 
of patients. At six months, TVF occurred in 2.6% of patients 
and device thrombosis in 0.9% of patients. Initial results for 
240 patients (FANTOM II study; Cohorts A and B) have shown 
a TVF rate of 4.2% and definite device thrombosis rate of 
0.4% (single sub-acute thrombosis) at 12 months [Abizaid, 
EuroPCR 2017]. These excellent results were maintained 
for up to 24 months with TVF of 5.0% and definite or prob-
able scaffold thrombosis of 0.8% [Abizaid, EuroPCR 2018]. 
Five-year follow-up is pending. A case example of a Fantom 
scaffold implantation is shown in Figure 6. In February 2018, 
the company achieved CE mark approval for a new generation 
device called Fantom Encore BRS, with 2.5-mm diameter and 
reduced strut profile (95 µm).
ART BIORESORBABLE SCAFFOLD
The ART bioresorbable scaffold is made from a PDLLA 
amorphous polymer. It received CE mark approval in May 
2015. Notably, the device does not contain an anti-pro-
liferative drug. The lack of an anti-proliferative drug was 
suggested to be associated with early endothelial coverage 
of the ART BRS based on animal studies. This rapid degrada-
tion of the ART BRS might lead to reduced risk of late device 
thrombosis. However, this concept should be confirmed in 
further studies. So far, only one study (ARTDIVA) [Lafont, BRS 
2014; Lafont, TCT 2016] reported clinical and angiographic 
outcomes of the ART BRS. In a group of 30 patients, at six 
months only one (3.3%) ischaemia-driven TLR was reported. 
MAGMARIS BIORESORBABLE  
MAGNESIUM SCAFFOLD
The Magmaris BRS, formerly known as DREAMS 2G, is the 
first sirolimus-eluting, bio-corrodible metallic BRS (Fig. 1C). 
It gained CE mark approval in June 2016. It is the successor 
to the paclitaxel-eluting DREAMS platform [56]. Thanks to 
its metallic alloy, Magmaris BRS is believed to have better 
lesion crossing, trackability, and pushability than polymeric 
BRSs. The DREAMS 2G was tested in the non-randomised 
BIOSOLVE-II study including 123 patients [57]. At six months, 
TLF was observed in 3.3% of patients, with 0.8% cardiac 
death, 0.8% periprocedural MI, and 1.7% ischaemia-driven 
TLR [57]. These encouraging results were sustained for 
12 months; no additional events were observed beyond the 
six-month follow-up [58, 59]. During the entire follow-up of 
36 months none of the patients experienced a definite or 
probable scaffold thrombosis. The TLF rate at 36 months was 
6.8%. Similarly, in the initial cohort of 200 patients enrolled 
in the BIOSOLVE-IV study, 4.6% of patients experienced TLF 
and 0.5% had definite or probable scaffold thrombosis at 
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12 months after Magmaris BRS implantation [Lee, EuroPCR 
2018]. Importantly, this single event of scaffold thrombosis 
occurred in a patient who terminated DAPT early (five days) 
after implantation. Serial intracoronary imaging following 
implantation of the Magmaris BRS confirmed restoration of 
the vessel geometry, vasomotion, and bioresorption signs 
for up to 12 months [60]. Importantly, these changes oc-
curred with preservation of the lumen size between six and 
12 months. Notably, in an animal model, neoatherosclerosis 
was significantly reduced with the Magmaris BRS as compared 
to a metallic stent with identical design, geometry, and drug 
coating [Joner, ESC 2017]. Thus, so far, magnesium-based 
scaffolds fulfil the main assumptions of vascular restoration 
therapy: support, resorption, and restoration. However, no 
randomised clinical trial results are available to date.
OTHER DEVICES
Apart from BRS technologies that are already CE-marked, 
several BRS devices are under clinical and preclinical in-
vestigation (Table 1). These include, but are not limited to, 
MeRes100 (Meril Life Sciences, India; Fig. 1F), Mirage (Manli 
Cardiology, Singapore; Fig. 1G), NeoVas (Lepu Medical Tech-
nology, China), Renuvia (Boston Scientific, MA, USA), Apti-
tude and Magnitude (Amaranth Medical, CA, USA), Xinsorb 
(HuaAn Biotechnology, UK), Firesorb (MicroPort, China), 
Unity (QualiMed, Germany; Fig. 1E), and Falcon (Abbott 
Vascular, CA, USA). Some of them have unique features. For 
instance, the Renuvia has increased over-expansion capabil-
ity. This BRS uses a Synergy DES delivery system, which may 
allow for good deliverability and trackability of the device. 
This technology is already being tested in the RENUVIA FAST 
study. The main feature of the Mirage BRS is its helicoidal 
structure, which allows enhanced flexibility and low crossing 
profile. The radial strength of the device is comparable to other 
BRS and metallic stents. In addition, the mono-fibre circular 
struts of the Mirage were suggested to penetrate better into 
the vessel wall than the quadratic struts of other BRS and to 
cause less peri-strut shear stress and disturbance in the coro-
nary blood flow [61]. A randomised study in 60 patients with 
CAD was conducted to assess outcomes of the Mirage vs. the 
Absorb BRS [62]. At 12 months, the median in-scaffold late 
luminal loss was comparable for the Mirage and the Absorb 
(0.37 vs. 0.23 mm; p = 0.52). However, angiographic median 
in-scaffold diameter stenosis was significantly higher for the 
Mirage (28.6% vs. 18.2%; p = 0.046) [62]. No difference 
in clinical endpoints was observed (TLF: 17.2% vs. 14.8%; 
p = 0.73), with a single (3.4%) definite subacute device throm-
bosis in the Mirage group. The MeRes100 BRS has a hybrid 
cell design (closed cells at the edges and open cells along 
the length), which allows optimal vessel wall conformability 
and high radial strength. The couplets of tri-axial platinum 
radiopaque markers may facilitate the device positioning [63]. 
In the MeRes-1 first-in-human trial 108 patients (116 lesions) 
were treated with the MeRes100. At six months, quantitative 
coronary angiography confirmed no binary restenosis, with 
in-scaffold late lumen loss of 0.15 ± 0.23 mm. The rate of 
TLF was 0.93% at 12 months and 1.87% at 24 months, with 
no events of device thrombosis [63] [Chandra, EuroPCR 
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Figure 6. A case example of a 65-year-old female patient with stable angina treated with Fantom scaffold (the FANTOM II study); 
A. Baseline angiography with 80% stenosis of the left anterior descending artery (arrow) and an optimal result of the previous 
implantation of a metallic drug-eluting stent in the left circumflex artery; B. Final angiography and optical coherence tomography 
(OCT) after successful implantation of the Fantom scaffold 3.0 × 18 mm up to 14 atm and postdilatation with non-compliant 
balloon 3.25 × 6 mm up to 16 atm (arrow); C. Six-month control angiography and OCT with a maintained optimal result of 
scaffold implantation; D. Two-year control angiography with a maintained optimal result of scaffold implantation. Complete 
coverage of the scaffold struts confirmed by OCT (arrow)
A B
C D
2018]. The Xinsorb is characterised by good deliverability 
and fast drug release (80% of drug eluted in 28 days ex vivo). 
Initial results for 30 patients showed encouraging results with 
in-scaffold late lumen loss of 0.17 ± 0.12 mm and no device 
thrombosis at six months [64]. Recently presented results of 
the randomised XINSORB study [Ge, TCT 2017] have con-
firmed that the Xinsorb is not inferior to a biodegradable-poly-
mer-based sirolimus-eluting stent (Tivoli stent) regarding 
peri-device late lumen loss (Xinorb vs. Tivoli: 0.19 ± 0.32 mm 
vs. 0.31 ± 0.41 mm; p < 0.001) at one year. The rates of 
TLF and definite or probable device thrombosis for the Xin-
sorb at one year were 1.6% and 0.5%, respectively. Similarly, 
a first-in-man study with the NeoVas has shown promising 
clinical and multimodality imaging results at six months, with 
no events of device thrombosis. In a head-to-head comparison 
with cobalt-chromium everolimus-eluting stent [65], the Neo-
Vas proved to be less effective in terms of device success than 
metallic DES. On the other hand, the NeoVas was not inferior 
regarding in-scaffold late lumen loss at one year as compared 
to the control. The rates of TLF and device thrombosis were 
comparable between groups (NeoVas vs. control: TLF 4.3% 
vs. 3.5%; p = 0.64, definite or probable device thrombosis 
0.4% vs. 0.0%; p = 0.50). The Unity BRS was initially devel-
oped as a biliary/peripheral vascular stent. However, perfor-
mance of the device in coronary arteries is now being tested 
in animal models. Similarly to the Magmaris BRS, the Unity 
BRS consists of a magnesium core and polymer outer. Thus, 
its usability and mechanical properties seem to be compa-
rable to regular metallic stents. Recently presented data from 
the RENASCENT II study with an Aptitude scaffold (115 µm) 
and the RENASCENT III study with the Magnitude scaffold 
(98 µm) have confirmed excellent device performance with 
no cases of device thrombosis [Chieffo, EuroPCR 2018]. The 
successor to these devices is going to be a new 85-µm scaffold 
called Defiance. The Absorb technology is currently under 
refinement, and the next generation of the Absorb, referred 
to sometimes as the Falcon, is under preclinical testing. The 
new scaffold is expected to have thinner struts (< 100 µm), 
and improved deliverability and acute performance [11].
RECOMMENDATIONS FOR THE USE AND  
EVALUATION OF BIORESORBABLE SCAFFOLDS
Recently the ESC-EAPCI Task Force issued practical guid-
ance on the evaluation and use of BRSs in patients with 
CAD undergoing PCI [12]. This deals mainly with the Absorb 
BRS because most of the clinical evidence comes from the 
ABSORB studies. The primary reason for such guidance was 
the higher than expected rate of very late device thrombosis 
reported for the Absorb BRS. Also, available evidence sug-
gested no clear late advantage regarding clinical efficacy for 
the Absorb. Thus, the ESC-EAPCI Task Force concluded that 
BRS should not be preferred over current generation DESs 
in everyday clinical practice. Importantly, all on-going stud-
ies should be thoroughly monitored for adverse events and 
achieved data should be published regularly. As mentioned 
before, BRS should not be recommended in patients who 
cannot tolerate prolonged DAPT or who require treatment 
with oral anticoagulants [12].
Apart from patient selection, proper lesion selection 
and preparation seems crucial to achieve optimal results of 
BRS implantation. According to the ESC-EAPCI Task Force 
document, the use of BRS is strongly discouraged in heavily 
calcified vessels [12, 66]. Also, its use is not recommended in 
coronary arteries with RVD < 2.5 mm. Operators should be 
strongly encouraged to use intracoronary imaging for lesion 
assessment. Also, lesions should be routinely predilated with 
noncompliant balloons with the size of the estimated RVD. In 
the case of non-complete balloon expansion, even after the 
use of plaque modification techniques, the implantation of 
BRS should be abandoned. If more than one BRS is required, 
excessive scaffold overlap should be avoided and preferably 
a device-to-device technique should be applied. In all cases, 
high-pressure postdilatation with a noncompliant balloon is 
recommended. The size of the balloon should not exceed 
0.5 mm over the nominal diameter of the device [12]. 
To ensure the highest safety control level, the ESC-EAPCI 
Task Force recommends an evaluation plan for BRS [12]. 
The preclinical testing should include characterisation of the 
finished product and mechanical testing. Bench and in vivo 
testing in animal models should follow strict recommendations 
[12]. Importantly, the duration of follow-up should be sufficient 
to capture all relevant biological processes pertaining to stent 
safety. In addition, determination of BRS degradation products 
as well as drug concentrations in blood and major organs is 
required. The clinical part of the plan assumes pre-CE-mark 
phase and post-CE-mark phase. The former should include ini-
tial human feasibility studies with BRS based on intravascular 
imaging evaluation and angiographic follow-up (small-sized, 
selected patients) and a subsequent randomised trial based on 
surrogate endpoints (medium-sized, comparator device). The 
latter phase should include a large-scale, clinical, randomised 
trial with long-term (preferably five-year) follow-up. Impor-
tantly, such a trial should be powered to confirm superiority 
over the comparator.
CONCLUSIONS
Despite some expected benefits of BRS, none of the available 
data have confirmed the advantage of the first-generation 
BRS over the metallic DES. Thus, the current generations of 
BRS, especially the Absorb BRS, should not be preferred to 
conventional DES in everyday clinical practice. On the other 
hand, the concept of vascular restoration therapy with BRS 
should not be abandoned. Next generations of BRS should 
aim not only to improve the acute performance of the device 
but, above all, long-term safety. However, the improvement 
might be achieved not only by device refinement but also 
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with a proper technique of implantation, intravascular imag-
ing guidance, as well as careful patient and lesion selection. 
As recommended by the ESC-EAPCI Task Force, all new BRS 
devices should be thoroughly evaluated in preclinical and 
clinical studies with planned long-term follow-up. These 
studies may allow confirmation of the presence of other pos-
sible benefits of BRS, including recovery of vasomotion and 
improved vessel healing. Thus, we still have to wait for the 
next revolution in the field of PCI. However, thanks to very 
encouraging long-term results with the FANTOM and MAG-
MARIS scaffolds, it is certain that the revolution will come.
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